Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Effects of cyclization on stability, structure, and activity of α-conotoxin RgIA at the α9α10 nicotinic acetylcholine receptor and GABA(B) receptor.

Halai R, Callaghan B, Daly NL, Clark RJ, Adams DJ, Craik DJ.

J Med Chem. 2011 Oct 13;54(19):6984-92. doi: 10.1021/jm201060r. Epub 2011 Sep 15.

PMID:
21888386
2.
3.

Structure and activity of alpha-conotoxin PeIA at nicotinic acetylcholine receptor subtypes and GABA(B) receptor-coupled N-type calcium channels.

Daly NL, Callaghan B, Clark RJ, Nevin ST, Adams DJ, Craik DJ.

J Biol Chem. 2011 Mar 25;286(12):10233-7. doi: 10.1074/jbc.M110.196170. Epub 2011 Jan 20.

4.

γ-Aminobutyric acid type B (GABAB) receptor expression is needed for inhibition of N-type (Cav2.2) calcium channels by analgesic α-conotoxins.

Cuny H, de Faoite A, Huynh TG, Yasuda T, Berecki G, Adams DJ.

J Biol Chem. 2012 Jul 6;287(28):23948-57. doi: 10.1074/jbc.M112.342998. Epub 2012 May 21.

5.

A novel mechanism of inhibition of high-voltage activated calcium channels by α-conotoxins contributes to relief of nerve injury-induced neuropathic pain.

Klimis H, Adams DJ, Callaghan B, Nevin S, Alewood PF, Vaughan CW, Mozar CA, Christie MJ.

Pain. 2011 Feb;152(2):259-66. doi: 10.1016/j.pain.2010.09.007.

PMID:
20889259
6.

Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation.

Callaghan B, Haythornthwaite A, Berecki G, Clark RJ, Craik DJ, Adams DJ.

J Neurosci. 2008 Oct 22;28(43):10943-51. doi: 10.1523/JNEUROSCI.3594-08.2008.

7.

Alpha-RgIA, a novel conotoxin that blocks the alpha9alpha10 nAChR: structure and identification of key receptor-binding residues.

Ellison M, Feng ZP, Park AJ, Zhang X, Olivera BM, McIntosh JM, Norton RS.

J Mol Biol. 2008 Apr 4;377(4):1216-27. doi: 10.1016/j.jmb.2008.01.082. Epub 2008 Feb 4.

8.

Dicarba analogues of α-conotoxin RgIA. Structure, stability, and activity at potential pain targets.

Chhabra S, Belgi A, Bartels P, van Lierop BJ, Robinson SD, Kompella SN, Hung A, Callaghan BP, Adams DJ, Robinson AJ, Norton RS.

J Med Chem. 2014 Dec 11;57(23):9933-44. doi: 10.1021/jm501126u. Epub 2014 Dec 1.

PMID:
25393758
9.

Scanning mutagenesis of alpha-conotoxin Vc1.1 reveals residues crucial for activity at the alpha9alpha10 nicotinic acetylcholine receptor.

Halai R, Clark RJ, Nevin ST, Jensen JE, Adams DJ, Craik DJ.

J Biol Chem. 2009 Jul 24;284(30):20275-84. doi: 10.1074/jbc.M109.015339. Epub 2009 May 15.

10.

Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII.

Clark RJ, Fischer H, Dempster L, Daly NL, Rosengren KJ, Nevin ST, Meunier FA, Adams DJ, Craik DJ.

Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13767-72. Epub 2005 Sep 14.

11.

Alpha-RgIA: a novel conotoxin that specifically and potently blocks the alpha9alpha10 nAChR.

Ellison M, Haberlandt C, Gomez-Casati ME, Watkins M, Elgoyhen AB, McIntosh JM, Olivera BM.

Biochemistry. 2006 Feb 7;45(5):1511-7.

PMID:
16445293
12.

Analgesic conotoxins: block and G protein-coupled receptor modulation of N-type (Ca(V) 2.2) calcium channels.

Adams DJ, Callaghan B, Berecki G.

Br J Pharmacol. 2012 May;166(2):486-500. doi: 10.1111/j.1476-5381.2011.01781.x. Review.

13.

The three-dimensional structure of the analgesic alpha-conotoxin, RgIA.

Clark RJ, Daly NL, Halai R, Nevin ST, Adams DJ, Craik DJ.

FEBS Lett. 2008 Mar 5;582(5):597-602. doi: 10.1016/j.febslet.2008.01.027. Epub 2008 Jan 31.

14.

Dicarba α-conotoxin Vc1.1 analogues with differential selectivity for nicotinic acetylcholine and GABAB receptors.

van Lierop BJ, Robinson SD, Kompella SN, Belgi A, McArthur JR, Hung A, MacRaild CA, Adams DJ, Norton RS, Robinson AJ.

ACS Chem Biol. 2013 Aug 16;8(8):1815-21. doi: 10.1021/cb4002393. Epub 2013 Jun 17.

PMID:
23768016
15.

Molecular interaction of α-conotoxin RgIA with the rat α9α10 nicotinic acetylcholine receptor.

Azam L, Papakyriakou A, Zouridakis M, Giastas P, Tzartos SJ, McIntosh JM.

Mol Pharmacol. 2015 May;87(5):855-64. doi: 10.1124/mol.114.096511. Epub 2015 Mar 4. Erratum in: Mol Pharmacol. 2016 Oct;90(4):415-7.

16.

Solving the alpha-conotoxin folding problem: efficient selenium-directed on-resin generation of more potent and stable nicotinic acetylcholine receptor antagonists.

Muttenthaler M, Nevin ST, Grishin AA, Ngo ST, Choy PT, Daly NL, Hu SH, Armishaw CJ, Wang CI, Lewis RJ, Martin JL, Noakes PG, Craik DJ, Adams DJ, Alewood PF.

J Am Chem Soc. 2010 Mar 17;132(10):3514-22. doi: 10.1021/ja910602h.

PMID:
20163143
17.

Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine receptor antagonist.

Luo S, Zhangsun D, Harvey PJ, Kaas Q, Wu Y, Zhu X, Hu Y, Li X, Tsetlin VI, Christensen S, Romero HK, McIntyre M, Dowell C, Baxter JC, Elmslie KS, Craik DJ, McIntosh JM.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4026-35. doi: 10.1073/pnas.1503617112. Epub 2015 Jul 13.

18.

Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels.

Berecki G, Motin L, Haythornthwaite A, Vink S, Bansal P, Drinkwater R, Wang CI, Moretta M, Lewis RJ, Alewood PF, Christie MJ, Adams DJ.

Mol Pharmacol. 2010 Feb;77(2):139-48. doi: 10.1124/mol.109.058834. Epub 2009 Nov 5.

19.

Molecular basis for the differential sensitivity of rat and human α9α10 nAChRs to α-conotoxin RgIA.

Azam L, McIntosh JM.

J Neurochem. 2012 Sep;122(6):1137-44. doi: 10.1111/j.1471-4159.2012.07867.x. Epub 2012 Aug 3.

20.

Cyclization of conotoxins to improve their biopharmaceutical properties.

Clark RJ, Akcan M, Kaas Q, Daly NL, Craik DJ.

Toxicon. 2012 Mar 15;59(4):446-55. doi: 10.1016/j.toxicon.2010.12.003. Epub 2010 Dec 10. Review.

PMID:
21147143

Supplemental Content

Support Center